Navigation Links
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
Date:5/20/2008

rcentage of men who received this treatment maintained normal testosterone levels while receiving an injection every 10 weeks. This form of testosterone treatment would thus require only five injections per year. This would be an appealing alternative for many men, who may object to existing testosterone treatments such as twice-monthly injections or daily skin application of gels or patches."

About the Study

This Phase III study was a multi-center, open-label, randomized US trial designed to assess the pharmacokinetics, safety, and efficacy of NEBIDO in men with primary or secondary hypogonadism. The trial enrolled a total of 130 hypogonadal men (serum testosterone below 300 ng/dL, at least 18 years of age) that met the study inclusion criteria. Patients received injections of 750 mg of NEBIDO at baseline, week 4, and week 14 of the study, and were followed for an additional 10 weeks. Of the 130 men who participated in the trial, 117 patients were eligible for pharmacokinetics evaluations.

In the study, pharmacokinetic objectives were achieved, with 94 percent of patients reaching and maintaining normal serum testosterone levels. Additionally, secondary endpoints of mood and sexual function also improved. The most commonly reported possibly-related adverse events in the trial were acne (4.6 percent), fatigue (3.1 percent), and injection site pain (3.1 percent).

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Today, there are an estimate
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
2. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. Indevus Announces Submission of New Drug Application
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... Columbus, OH (PRWEB) July 26, 2014 The ... medical guidelines list that includes a new medication guide for ... as a serious side-effect of taking the topical low testosterone ... notes that AbbVie Inc., the makers of the low testosterone ... include symptoms of pain, swelling or redness as signs of ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... updated by Vkool.com, this is a comprehensive guide that ... unwanted tattoos . This book also teaches them ... imitate common medical procedures in their own home for ... that "Get Rid Tattoo Naturally" book includes step-by-step tutorials ...
(Date:7/25/2014)... Texas (PRWEB) July 26, 2014 ... and China Gel Permeation Chromatography Industry” is ... the Global and China Gel Permeation Chromatography ... Chromatography information, including Gel Permeation Chromatography definition, ... well as industry overview. This research covers ...
(Date:7/25/2014)... July 25, 2014 A federal judge ... in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... the claims to go before a jury on September ... rendered on July 18th, U.S. District Judge Ed Kinkeade ... two Plaintiffs’ claims may proceed to trial against Johnson ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... -- People with heart conditions who take vitamins may be ... according to a new study. Researchers from the Intermountain ... heartbeat -- known as atrial fibrillation -- what they knew ... were also asked how well they followed their prescription for ...
... Healthy, new heart cells have been generated by animals ... derived from cardiac biopsies or "cardiospheres," according to research ... and Biomedical Sciences. , The research is being ... the American Heart Association in Orlando. , The UB ...
... which can develop into any cell type in the ... drive their metabolic activities. In contrast, mature ... mitochondria to convert sugar and oxygen into carbon dioxide ... phosphorylation for their metabolic needs. How cells ...
... surgical techniques on toy animals before having to perform operations ... the same time, the use of laboratory animals is minimised. ... - the Faculty of Life Sciences at the University of ... the ,teddy laboratory, strengthens learning and the teaching environment. ...
... -- Preliminary trials indicate that a new drug designed ... shows considerable promise, both on its own and in ... is part of a class of so-called "cholesteryl ester ... CETP medication to undergo testing as a means to ...
... Reinberg HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay ... the statin drug Zocor (simvastatin) to help lower their cholesterol ... Even though niacin appeared to increase HDL cholesterol -- the ... in the blood, it did not reduce the risk of ...
Cached Medicine News:Health News:Heart Patients Using Vitamins May Take Meds Improperly 2Health News:Heart Patients Using Vitamins May Take Meds Improperly 3Health News:New heart cells increase by 30 percent after stem cell infusion 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 3Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 4Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Cholesterol Drug Shows Promise in Early Research 2Health News:Cholesterol Drug Shows Promise in Early Research 3Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: